Monopar Therapeutics Inc (NASDAQ:MNPR)’s traded shares stood at 31.67 million during the latest session, with the company’s beta value hitting 1.15. At the last check today, the stock’s price was $4.17, to imply an increase of 73.94% or $1.77 in intraday trading. The MNPR share’s 52-week high remains $8.65, putting it -107.43% down since that peak but still an impressive 67.15% since price per share fell to its 52-week low of $1.37. The company has a valuation of $14.69M, with an average of 14670.0 shares in intraday trading volume over the past 10 days and average of 59.52K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Monopar Therapeutics Inc (MNPR), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give MNPR a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.48.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monopar Therapeutics Inc (NASDAQ:MNPR) trade information
After registering a 73.94% upside in the latest session, Monopar Therapeutics Inc (MNPR) has traded red over the past five days. The 5-day price performance for the stock is 71.79%, and 72.50% over 30 days. With these gigs, the year-to-date price performance is 145.42%. Short interest in Monopar Therapeutics Inc (NASDAQ:MNPR) saw shorts transact 29807.0 shares and set a 1.33 days time to cover.
Monopar Therapeutics Inc (MNPR) estimates and forecasts
Looking at statistics comparing Monopar Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Monopar Therapeutics Inc (MNPR) shares are 11.01% up over the last 6 months, with its year-to-date growth rate higher than industry average at 36.72% against 17.50%. Revenue is forecast to grow 31.40% this quarter before jumping 20.00% for the next one.
MNPR Dividends
Monopar Therapeutics Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Monopar Therapeutics Inc (NASDAQ:MNPR)’s Major holders
Monopar Therapeutics Inc insiders hold 53.29% of total outstanding shares, with institutional holders owning 2.38% of the shares at 5.09% float percentage. In total, 2.38% institutions holds shares in the company, led by MILLENNIUM MANAGEMENT LLC. As of 2024-06-30, the company held over 0.19 million shares (or 1.2159% of shares), all amounting to roughly $0.15 million.
The next major institution holding the largest number of shares is GEODE CAPITAL MANAGEMENT, LLC with 60036.0 shares, or about 0.3757% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $44906.0.
